SG11202007199XA - Anti-cd73 antibodies and uses thereof - Google Patents
Anti-cd73 antibodies and uses thereofInfo
- Publication number
- SG11202007199XA SG11202007199XA SG11202007199XA SG11202007199XA SG11202007199XA SG 11202007199X A SG11202007199X A SG 11202007199XA SG 11202007199X A SG11202007199X A SG 11202007199XA SG 11202007199X A SG11202007199X A SG 11202007199XA SG 11202007199X A SG11202007199X A SG 11202007199XA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fats And Perfumes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640955P | 2018-03-09 | 2018-03-09 | |
| US201862721044P | 2018-08-22 | 2018-08-22 | |
| US201862786598P | 2018-12-31 | 2018-12-31 | |
| PCT/US2019/020688 WO2019173291A1 (en) | 2018-03-09 | 2019-03-05 | Anti-cd73 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007199XA true SG11202007199XA (en) | 2020-09-29 |
Family
ID=67846304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007199XA SG11202007199XA (en) | 2018-03-09 | 2019-03-05 | Anti-cd73 antibodies and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11299550B2 (ko) |
| EP (1) | EP3762030A4 (ko) |
| JP (2) | JP7334177B2 (ko) |
| KR (1) | KR20200128542A (ko) |
| CN (1) | CN111867628A (ko) |
| AU (1) | AU2019231172B2 (ko) |
| BR (1) | BR112020016049A2 (ko) |
| CA (1) | CA3090008A1 (ko) |
| IL (1) | IL276950A (ko) |
| MX (1) | MX2020009366A (ko) |
| SG (1) | SG11202007199XA (ko) |
| WO (1) | WO2019173291A1 (ko) |
| ZA (1) | ZA202004827B (ko) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| JP2022548777A (ja) * | 2019-09-23 | 2022-11-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | マウスおよびヒト線維芽細胞活性化タンパク質（ｆａｐ）と交差反応するイヌ線維芽細胞活性化タンパク質に対するモノクローナル抗体 |
| WO2021097223A2 (en) * | 2019-11-15 | 2021-05-20 | Genzyme Corporation | Biparatopic cd73 antibodies |
| WO2021102376A1 (en) * | 2019-11-20 | 2021-05-27 | Abvision, Inc. | Monoclonal antibodies that target human cd47 protein |
| BR112022013236A2 (pt) * | 2020-01-03 | 2022-09-06 | Incyte Corp | Anticorpos anti-cd73 e usos dos mesmos |
| KR20220137013A (ko) | 2020-01-03 | 2022-10-11 | 인사이트 코포레이션 | Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법 |
| EP4126966A1 (en) | 2020-03-31 | 2023-02-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| US20230151111A1 (en) * | 2020-04-22 | 2023-05-18 | Akeso Biopharma, Inc | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| BR112022021992A2 (pt) * | 2020-04-30 | 2023-01-03 | Arch Oncology Inc | Método de tratamento de câncer em um sujeito em necessidade do mesmo |
| WO2022037531A1 (zh) * | 2020-08-17 | 2022-02-24 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| AU2021411952A1 (en) | 2020-12-29 | 2023-08-10 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
| CN113061177B (zh) * | 2020-12-31 | 2022-07-01 | 浙江大学 | 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法 |
| EP4299589A1 (en) * | 2021-02-24 | 2024-01-03 | Novoprotein Scientififc Inc. | Anti-human cd73 antibody and use thereof |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| AU2022331350A1 (en) * | 2021-08-19 | 2024-03-14 | Adicet Therapeutics, Inc. | Methods for detection of membrane bound glypican-3 |
| CN116265486A (zh) * | 2021-12-17 | 2023-06-20 | 三生国健药业（上海）股份有限公司 | 结合人cd73的抗体、其制备方法和用途 |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5382692B2 (ja) | 2006-07-10 | 2014-01-08 | 学校法人藤田学園 | 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| EP3134411B1 (en) | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| EP3204417B1 (en) * | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| SG11201703332SA (en) * | 2014-11-10 | 2017-05-30 | Medimmune Ltd | Binding molecules specific for cd73 and uses thereof |
| WO2016075176A1 (en) * | 2014-11-11 | 2016-05-19 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| CN113929770A (zh) | 2014-11-21 | 2022-01-14 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
| PL3221363T3 (pl) | 2014-11-21 | 2021-01-11 | Bristol-Myers Squibb Company | Przeciwciała przeciwko cd73 i ich zastosowanie |
| EP3259288A1 (en) * | 2015-02-20 | 2017-12-27 | Innate Pharma | Cd73 blockade |
| EP3362475B1 (en) | 2015-10-12 | 2023-08-30 | Innate Pharma | Cd73 blocking agents |
| MX2018006973A (es) * | 2015-12-09 | 2019-05-16 | Corvus Pharmaceuticals Inc | Anticuerpos anti-cd73 humanizados. |
| WO2017118613A1 (en) | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| BR112018067368A2 (pt) | 2016-03-04 | 2019-01-15 | Bristol-Myers Squibb Company | terapia de combinação com anticorpos anti-cd73 |
| EP3481869A4 (en) | 2016-07-11 | 2020-02-26 | Corvus Pharmaceuticals, Inc. | ANTI-CD73 ANTIBODY |
-
2019
- 2019-03-05 AU AU2019231172A patent/AU2019231172B2/en active Active
- 2019-03-05 CN CN201980018305.6A patent/CN111867628A/zh active Pending
- 2019-03-05 CA CA3090008A patent/CA3090008A1/en active Pending
- 2019-03-05 MX MX2020009366A patent/MX2020009366A/es unknown
- 2019-03-05 JP JP2020546997A patent/JP7334177B2/ja active Active
- 2019-03-05 BR BR112020016049-0A patent/BR112020016049A2/pt unknown
- 2019-03-05 KR KR1020207027633A patent/KR20200128542A/ko unknown
- 2019-03-05 WO PCT/US2019/020688 patent/WO2019173291A1/en active Application Filing
- 2019-03-05 US US15/733,540 patent/US11299550B2/en active Active
- 2019-03-05 SG SG11202007199XA patent/SG11202007199XA/en unknown
- 2019-03-05 EP EP19764477.6A patent/EP3762030A4/en active Pending
-
2020
- 2020-08-04 ZA ZA2020/04827A patent/ZA202004827B/en unknown
- 2020-08-26 IL IL276950A patent/IL276950A/en unknown
-
2023
- 2023-08-14 JP JP2023132024A patent/JP2023162257A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019231172B2 (en) | 2023-08-24 |
| US20200399389A1 (en) | 2020-12-24 |
| JP7334177B2 (ja) | 2023-08-28 |
| BR112020016049A2 (pt) | 2020-12-08 |
| WO2019173291A1 (en) | 2019-09-12 |
| US11299550B2 (en) | 2022-04-12 |
| EP3762030A1 (en) | 2021-01-13 |
| ZA202004827B (en) | 2023-06-28 |
| CN111867628A (zh) | 2020-10-30 |
| IL276950A (en) | 2020-10-29 |
| MX2020009366A (es) | 2020-10-14 |
| AU2019231172A1 (en) | 2020-09-03 |
| KR20200128542A (ko) | 2020-11-13 |
| EP3762030A4 (en) | 2022-01-05 |
| CA3090008A1 (en) | 2019-09-12 |
| JP2023162257A (ja) | 2023-11-08 |
| JP2021516057A (ja) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| IL267942B (en) | Anti-cd73 antibodies and uses thereof | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL268700A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
| IL281297A (en) | Anti-NPR1 antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| GB201712032D0 (en) | Antibodies and uses thereof | |
| IL283926A (en) | Antibodies against alpha-synuclein and their uses | |
| IL291546A (en) | Antibodies against kir3dl3 and their uses | |
| IL291550A (en) | Anti-il-27 antibodies and their uses | |
| IL291280A (en) | Antibodies against cd371 and their uses |